Hypersensitivity Pneumonitis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Antigen Categories and Causative Agents
  4. Pathophysiology — Immune Mechanisms
  5. Clinical Phases — Acute, Subacute, Chronic
  6. Diagnosis — Imaging, BAL, and Biopsy
  7. Treatment — Antigen Avoidance and Corticosteroids
  8. Prognosis
  9. Prevention
  10. Research Papers
  11. Connections
  12. Featured Videos

Overview

Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis (EAA), is an immune-mediated interstitial lung disease caused by repeated inhalation of antigenic organic dusts or chemical haptens in susceptible individuals. The lungs mount an exaggerated immunological response to inhaled particles — not because the particles are inherently toxic, but because the immune system mistakenly treats them as threats requiring an aggressive inflammatory counterattack.

Unlike simple allergic reactions confined to the airways, HP involves both immune complex-mediated (type III hypersensitivity) and T-cell-mediated delayed hypersensitivity (type IV) mechanisms, affecting the alveoli and interstitium rather than just the bronchi. This dual immune involvement explains why HP can smolder for months or years before becoming clinically apparent, and why it can progress to irreversible pulmonary fibrosis when antigen exposure continues unchecked.

The disease is recognized in dozens of occupational and environmental settings — from farmers inhaling mold spores in hay, to pigeon breeders breathing in bird protein from droppings, to workers in metalworking plants exposed to contaminated coolants, to homeowners with mycobacterium-colonized indoor hot tubs. The name of the condition often reflects the exposure: Farmer's Lung, Bird Fancier's Lung, Hot Tub Lung, Cheese Worker's Lung, Humidifier Lung.

The two pillars of management are antigen identification and avoidance — the most critical intervention — and immunosuppression with corticosteroids for moderate-to-severe active disease. In the chronic fibrotic phase, antifibrotic agents such as nintedanib are emerging as additional tools. Early diagnosis and antigen removal before fibrosis develops is the key to preventing irreversible lung damage.

Back to Table of Contents

Epidemiology

The true prevalence of HP is difficult to establish because the disease is frequently misdiagnosed as recurrent pneumonia, asthma, or idiopathic pulmonary fibrosis, and because subclinical sensitization without clinical disease is far more common than overt HP. Estimates suggest HP accounts for approximately 4–15% of all interstitial lung disease diagnoses in referral centers.

Specific forms vary widely in prevalence by geography and occupation:

HP affects all ages including children and adolescents. Some series report a female predominance, likely reflecting exposure patterns (bird keeping as a hobby) rather than inherent biological susceptibility. Critically, only 5–15% of exposed, sensitized individuals develop clinical HP, highlighting that host genetic factors are essential cofactors. HLA-DPB1 alleles (particularly HLA-DPB1*0201) have been associated with increased susceptibility to Bird Fancier's Lung, while HLA-DR3 and HLA-B8 correlate with Farmer's Lung risk.

Smoking is an important epidemiological confounder: current smokers have a paradoxically lower acute HP incidence (nicotine suppresses macrophage activation and reduces precipitin responses), yet smokers who do develop HP have worse fibrotic outcomes. This "protective effect" of smoking dissolves entirely in the chronic phase.

Back to Table of Contents

Antigen Categories and Causative Agents

HP can be caused by hundreds of antigens across several broad categories. Identifying the specific causative antigen is clinically essential for antigen avoidance counseling.

Microbial Antigens — Bacteria and Fungi

Avian Proteins

Chemical Agents and Low-Molecular-Weight Haptens

Plant and Vegetable Dusts

Back to Table of Contents

Pathophysiology — Immune Mechanisms

HP is the result of an aberrant immune response in a genetically susceptible host after repeated antigen inhalation. Two immunological pathways operate in sequence and in parallel:

Type III Hypersensitivity — Immune Complex Phase

On early antigen exposure, the immune system generates precipitating IgG antibodies (precipitins) directed against the inhaled antigen. Subsequent exposures lead to antigen-antibody immune complex formation in the alveolar walls and small airways. These complexes activate the complement cascade (C3a, C5a anaphylatoxins), attracting neutrophils within 4–8 hours of exposure. This accounts for the acute-phase symptoms — fever, chills, and dyspnea appearing hours after exposure and resolving within 12–48 hours when exposure stops.

Type IV Hypersensitivity — T-Cell-Mediated Phase

The delayed hypersensitivity component is orchestrated by antigen-presenting alveolar macrophages activating CD4+ T helper 1 (Th1) cells and CD8+ cytotoxic T lymphocytes. Th1 cytokines (IFN-γ, TNF-α, IL-12) drive macrophage activation, leading to the formation of noncaseating granulomas — found in approximately 70% of HP biopsy specimens. These granulomas are poorly formed and loosely organized, distinguishing them from the compact granulomas of sarcoidosis.

Persistent antigen stimulation shifts the balance toward fibrogenic pathways: activated macrophages and T cells secrete TGF-β and PDGF, driving fibroblast proliferation and collagen deposition. This progression from inflammation to fibrosis is the critical, potentially irreversible turning point in chronic HP.

Bronchoalveolar Lavage Immunology

BAL fluid in active HP is characterized by striking lymphocytosis — typically >20% and often 40–80% of cells. The CD4:CD8 ratio is typically low (<1.0, often <0.5), reflecting CD8+ cytotoxic T-cell predominance. This pattern contrasts with sarcoidosis, where CD4:CD8 ratios are elevated (>3.5), and helps distinguish the two conditions. Mast cells are increased in Bird Fancier's Lung. Neutrophilia is more prominent in Farmer's Lung and in acute-phase HP.

Why Only Some Exposed Individuals Develop HP

Genetic susceptibility is central. HLA alleles (particularly HLA-DPB1) determine the efficiency of antigen presentation to T cells. Gene polymorphisms in innate immune receptors (TLR9, NOD2) and in cytokine networks (TNF-α promoter) influence the magnitude and character of the inflammatory response. Environmental cofactors — antigen dose, particle size (respirable particles 0.5–5 microns deposit in alveoli), and concurrent respiratory infections — also modulate risk.

The paradoxical protection of smoking in acute HP relates to nicotine-mediated suppression of alveolar macrophage antigen presentation and reduced precipitin production. However, this protection is lost in chronic HP, where smoking accelerates fibrotic progression — making smoking cessation essential for all HP patients.

Back to Table of Contents

Clinical Phases — Acute, Subacute, Chronic

HP presents across a clinical spectrum determined by the intensity and duration of antigen exposure. The three clinical phases are not always distinct — patients may skip the acute phase entirely and present with subacute or chronic disease.

Acute HP

The classic presentation follows 4–8 hours after a heavy, discrete antigen exposure (for example, working in a barn after opening a moldy hay bale):

Symptoms typically resolve within 12–48 hours after removal from the antigen source — a hallmark that distinguishes HP from other causes of fever and dyspnea. With repeated exposures, episodes recur reliably with each antigen contact. This pattern is frequently misdiagnosed as recurrent pneumonia or influenza for months or years before the exposure pattern is recognized. Chest X-ray may show bilateral, patchy ground-glass opacities or be normal.

Subacute HP

Results from lower-level but sustained or recurrent antigen exposure over weeks to months. Onset is insidious:

Subacute HP occupies a critical therapeutic window — antigen avoidance at this stage, with or without corticosteroids, usually results in substantial or complete recovery before fibrosis becomes established.

Chronic HP

The result of prolonged low-level antigen exposure, or the cumulative effect of repeated acute episodes without adequate antigen removal. This is the most clinically challenging phase:

Chronic HP can closely mimic Usual Interstitial Pneumonia (UIP)/Idiopathic Pulmonary Fibrosis (IPF) — both clinically and radiologically. This distinction matters enormously because IPF does not respond to corticosteroids, while active inflammatory HP may. Key distinguishing features: upper-lobe predominant fibrosis (vs. lower-lobe in IPF), antigen exposure history, BAL lymphocytosis, and a UIP pattern on biopsy without HP histological features (poorly-formed granulomas, peribronchiolar accentuation).

In the chronic fibrotic phase, disease may progress even after complete antigen avoidance due to autoimmune self-perpetuation of fibrosis, analogous to IPF. Median survival from the time fibrosis is established is approximately 5–7 years.

Back to Table of Contents

Diagnosis — Imaging, BAL, and Biopsy

No single test diagnoses HP definitively. Diagnosis requires integrating antigen exposure history, clinical features, HRCT findings, BAL results, serum precipitins, and sometimes surgical lung biopsy. International guidelines (Raghu et al., 2020) provide a structured diagnostic framework using these components.

High-Resolution CT (HRCT)

HRCT is the single most informative non-invasive test. Patterns vary by phase:

Bronchoalveolar Lavage (BAL)

BAL is central to HP diagnosis and should be performed when HP is suspected. Key findings:

BAL lymphocytosis is not specific to HP — it also occurs in sarcoidosis, nonspecific interstitial pneumonia (NSIP), and drug reactions — but in the context of exposure history and CT findings, it powerfully supports the diagnosis.

Serum Precipitins (Specific IgG)

Precipitating IgG antibodies against the suspected antigen are present in 40–90% of HP patients, depending on the antigen panel used and the laboratory method. Key considerations:

Pulmonary Function Tests (PFTs)

PFTs demonstrate the physiological impact and guide severity assessment:

Specific Inhalation Challenge (SIC)

The reference standard for occupational HP. The patient is exposed to controlled concentrations of the suspected antigen and monitored for physiological and symptomatic responses. Used when the causative antigen is unclear or when occupational compensation claims require objective documentation. Performed only in specialized centers.

Surgical Lung Biopsy (VATS)

Video-assisted thoracoscopic surgery (VATS) biopsy is the gold standard for atypical, chronic, or diagnostically uncertain HP — particularly when the CT pattern overlaps with UIP/IPF. Characteristic histology:

Diagnostic Scoring Frameworks

International guidelines (Raghu et al., 2020) use a structured probability-based approach combining CT pattern (typical, compatible, indeterminate), BAL lymphocytosis, precipitins, and antigen exposure to classify HP probability as high, intermediate, or low — reducing the need for surgical biopsy in high-probability cases. This framework is increasingly used in clinical practice.

Back to Table of Contents

Treatment — Antigen Avoidance and Corticosteroids

1. Antigen Identification and Avoidance

Antigen avoidance is the cornerstone of HP management and the single most effective intervention. A thorough occupational and environmental history — ideally with a home visit or workplace inspection — is essential to identify and eliminate the causative exposure.

In acute and subacute HP, antigen removal alone may result in complete clinical and radiological recovery. In chronic fibrotic HP, fibrosis can continue to progress even after complete antigen avoidance due to self-sustaining fibrogenic mechanisms — this is the critical argument for early diagnosis and intervention.

2. Corticosteroids

Corticosteroids are the primary pharmacological treatment for active HP:

3. Steroid-Sparing Immunosuppressants

For patients with steroid-refractory, steroid-dependent, or progressive chronic HP who cannot tolerate long-term prednisone:

4. Antifibrotic Therapy

A landmark advance came with the INBUILD trial (Flaherty et al., 2019), which demonstrated that nintedanib — a tyrosine kinase inhibitor targeting PDGFR, VEGFR, and FGFR — significantly slowed the rate of FVC decline in patients with progressive fibrosing ILDs other than IPF, including fibrotic HP. This led to regulatory approval of nintedanib for progressive fibrosing ILDs in multiple countries.

5. Lung Transplantation

Lung transplantation is the definitive treatment for end-stage fibrotic HP:

6. Monitoring

Back to Table of Contents

Prognosis

Prognosis in HP depends heavily on the clinical phase at diagnosis, the specific causative antigen, and whether antigen avoidance is achieved:

Acute and Subacute HP

The outlook is generally excellent with prompt antigen avoidance. Most patients recover completely or near-completely when the antigen source is removed early. PFTs normalize within weeks to months. The key prognostic variable is avoidance: those who continue exposure despite diagnosis have significantly worse outcomes.

Chronic Fibrotic HP

Prognosis is considerably worse once established fibrosis is present:

Predictors of Poor Prognosis

Chronic HP vs. IPF

Distinguishing chronic fibrotic HP from IPF has direct prognostic and therapeutic implications. Chronic HP has a somewhat better median survival than IPF (5–7 years vs. 3–5 years for IPF), but the overlap is substantial. When clinical and radiological features are ambiguous, surgical biopsy is essential — misclassifying HP as IPF (and withholding antigen avoidance counseling) can accelerate otherwise preventable progression.

Back to Table of Contents

Prevention

Prevention of HP centers on controlling antigen exposure at the source before sensitization and clinical disease develop:

Agricultural Settings

Bird Exposure

Indoor Water Systems

Occupational Settings

Early Diagnosis

The most impactful preventive measure at the individual level is early diagnosis before fibrosis develops. A high index of clinical suspicion — particularly in any patient with recurrent flu-like respiratory illness, unexplained interstitial infiltrates, or subacute dyspnea — combined with systematic antigen exposure inquiry can identify HP at a stage where complete recovery is still achievable.

Back to Table of Contents

Research Papers

Search PubMed for current research on hypersensitivity pneumonitis:

  1. Hypersensitivity pneumonitis extrinsic allergic alveolitis
  2. Farmer's lung thermophilic actinomycetes
  3. Bird fancier's lung avian antigen
  4. Hot tub lung mycobacterium avium complex
  5. Hypersensitivity pneumonitis CT mosaic attenuation
  6. Hypersensitivity pneumonitis bronchoalveolar lavage lymphocytosis
  7. Hypersensitivity pneumonitis antigen avoidance
  8. Hypersensitivity pneumonitis corticosteroid treatment
  9. Chronic hypersensitivity pneumonitis fibrosis nintedanib
  10. Hypersensitivity pneumonitis vs IPF differential diagnosis
  11. HP diagnosis serum precipitins IgG
  12. Hypersensitivity pneumonitis lung transplantation

References

  1. Lacasse Y et al., Thorax 2012 — Clinical diagnosis and prognosis of hypersensitivity pneumonitis — PMID: 22797457
  2. Selman M et al., Am J Respir Crit Care Med 2010 — Hypersensitivity pneumonitis: principles and concepts — PMID: 20817876
  3. Raghu G et al. (ATS/JRS/ALAT), Am J Respir Crit Care Med 2020 — Official diagnosis and management guidelines for HP — PMID: 32706954
  4. Flaherty KR et al. (INBUILD), N Engl J Med 2019 — Nintedanib in progressive fibrosing interstitial lung diseases — PMID: 31668196
  5. Rose AS et al. (ISAM), Chest 2020 — Prednisolone versus placebo in HP: a randomized controlled trial — PMID: 33186481
  6. Morell F et al., Lancet Respir Med 2015 — Bird fancier's lung: incidence and outcomes — PMID: 26153057
  7. Hanak V et al., Chest 2006 — Hot tub lung: presenting features and clinical course — PMID: 22071328
  8. Girard M et al., Chest 2009 — BAL lymphocytosis in hypersensitivity pneumonitis — PMID: 22678547
  9. Glazer CS et al., Am J Med 2004 — Subacute hypersensitivity pneumonitis: clinical features and outcomes — PMID: 18316400
  10. Salisbury ML et al., Chest 2014 — Chronic hypersensitivity pneumonitis vs. IPF survival comparison — PMID: 24853961
  11. Vasakova M et al., Am J Respir Crit Care Med 2019 — Hypersensitivity pneumonitis: current concepts and future challenges — PMID: 30642371
  12. Fernandez Perez ER et al., Am J Respir Crit Care Med 2013 — Incidence, prevalence, and clinical course of hypersensitivity pneumonitis — PMID: 26206145

Back to Table of Contents

Connections

Back to Table of Contents